Immunome (IMNM) Short-term Investments (2023 - 2025)

Immunome has reported Short-term Investments for 3 years, with the latest figure at $124.2 million in Q2 2025.

• For the quarter ending Q2 2025, Short-term Investments rose 9.89% year-over-year to $124.2 million; the trailing twelve-month figure through Jun 2025 stood at $124.2 million (up 9.89% YoY), and the FY2024 full-year result was $74.0 million, up 87.4% from the prior year.
• Short-term Investments for Q2 2025 stood at $124.2 million, up from $59.7 million in the prior quarter.
• The five-year high for Short-term Investments was $124.2 million in Q2 2025, with the low at $39.5 million in Q4 2023.
• Historically, Short-term Investments has averaged $76.4 million across 3 years, with a median of $74.0 million in 2024.
• Annual changes were most pronounced in 2024 — Short-term Investments soared 87.4% — and 2025, when it rose 9.89%.
• Immunome's Short-term Investments stood at $39.5 million in 2023, then surged by 87.4% to $74.0 million in 2024, then soared by 67.95% to $124.2 million in 2025.
• The last three Short-term Investments figures came in at $124.2 million (Q2 2025), $59.7 million (Q1 2025), and $74.0 million (Q4 2024), per Business Quant data.